The Hospice Caregiver Assessment: A Study of a Case Management Tool for Professional Assistance

1989 ◽  
Vol 29 (1) ◽  
pp. 128-132 ◽  
Author(s):  
M. J. Etten ◽  
J. I. Kosberg
Author(s):  
Alan Shih ◽  
Corey Shum ◽  
Mark Dillavou ◽  
Ralph Noack ◽  
Bharat Soni ◽  
...  

Author(s):  
Audria Choudhury

Case management can be a complex process where multiple factors must be considered for the safety and well-being of a child in any care option. Miracle Foundation’s proprietary Home Thrive ScaleTM is a strengths-based assessment tool that makes it easier to identify strengths, risks and address areas of support within a family home over time. A home’s safety is measured based on five well-being domains—family and social relations, health and mental health, education, living conditions and household economy—with the child and family’s thoughts at the core. Intervention options are then offered to put assessments into action. The tool serves to both prevent family breakdowns and reintegrate children from institutions back into families (or other family-based or alternative care options). Here, we provide an overview of the tool, including its purpose, set-up and functionality within a case management system. The use of the tool is illustrated with the COVID-19 situation in India where masses of children were rapidly placed from institutions back into families without preparation.


2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Jane Cunningham ◽  
Sophie Jones ◽  
Michelle L. Gatton ◽  
John W. Barnwell ◽  
Qin Cheng ◽  
...  

AbstractMalaria rapid diagnostic tests (RDTs) emerged in the early 1990s into largely unregulated markets, and uncertain field performance was a major concern for the acceptance of tests for malaria case management. This, combined with the need to guide procurement decisions of UN agencies and WHO Member States, led to the creation of an independent, internationally coordinated RDT evaluation programme aiming to provide comparative performance data of commercially available RDTs. Products were assessed against Plasmodium falciparum and Plasmodium vivax samples diluted to two densities, along with malaria-negative samples from healthy individuals, and from people with immunological abnormalities or non-malarial infections. Three measures were established as indicators of performance, (i) panel detection score (PDS) determined against low density panels prepared from P. falciparum and P. vivax wild-type samples, (ii) false positive rate, and (iii) invalid rate, and minimum criteria defined. Over eight rounds of the programme, 332 products were tested. Between Rounds 1 and 8, substantial improvements were seen in all performance measures. The number of products meeting all criteria increased from 26.8% (11/41) in Round 1, to 79.4% (27/34) in Round 8. While products submitted to further evaluation rounds under compulsory re-testing did not show improvement, those voluntarily resubmitted showed significant increases in P. falciparum (p = 0.002) and P. vivax PDS (p < 0.001), with more products meeting the criteria upon re-testing. Through this programme, the differentiation of products based on comparative performance, combined with policy changes has been influential in the acceptance of malaria RDTs as a case-management tool, enabling a policy of parasite-based diagnosis prior to treatment. Publication of product testing results has produced a transparent market allowing users and procurers to clearly identify appropriate products for their situation, and could form a model for introduction of other, broad-scale diagnostics.


2015 ◽  
Vol 8 (1) ◽  
Author(s):  
Saskia Preissner ◽  
Eckehard Kostka ◽  
Mareike Mokross ◽  
Nina V. Kersten ◽  
Uwe Blunck ◽  
...  

2020 ◽  
Author(s):  
Carl Islam

Abstract The author’s premise is that in claims allocated to the multi-track, Judicial-Early Neutral Evaluation ('JENE') is the new normal. He discusses: the rationale; jurisdiction; and powers of the court to order JENE; its benefits; and the procedure. He concludes that, except where a claim involves the interests of minors and unborn beneficiaries, use of this case management tool is likely to become increasingly routine at the first case management conference where, for example, one party has proposed JENE, and the other has refused consent because he prefers mediation. Whereas mediation requires consent, JENE does not, and the court has the power at the first Case Management Conference to order a stay during which the parties must: (i) take stock and (ii) each carry out a reality check, i.e. before substantial costs are incurred in preparing for trial. Therefore, in an appropriate case, where a binary outcome on liability can open the door to settlement in relation to quantum, relief, and costs, JENE should be considered.


Sign in / Sign up

Export Citation Format

Share Document